Centene Corporation (NYSE:CNC) is one of the most profitable value stocks to buy according to analysts. On July 28, Truist lowered its price target on Centene to $35 from $42 but maintained a Buy rating on the shares following the company’s Q2 2025 results. Truist noted better performance in Centene’s Prescription Drug Plan/PDP and Medicare Advantage lines of business.
In Q2 2025, the company reported premium and service revenue of $42.5 billion, which contributed to total revenues of $48.7 billion. However, Centene reported an adjusted diluted loss per share of $0.16 for Q2 2025, which missed analyst expectations for a profit, and a GAAP diluted loss per share of $0.51. The Marketplace business also faced a $2.4 billion full-year headwind expected for 2025.
A doctor holding a clipboard in a hospital ward, discussing patient treatment plan with the nurses.
For 2026, Centene aims to reprice 100% of its book to improve profitability and focus on margin over membership. The company is also advocating for greater transparency and earlier data availability to improve market stability.
Centene Corporation is a healthcare enterprise that provides programs and services to under-insured and uninsured families, and commercial organizations in the US.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
This article is originally published at Insider Monkey.
